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Abstract. Biologically active small molecules repre-
sent the basis for chemical biology applications in
which small molecules are used as chemical tools to
probe biological processes. In this report, we review
two approaches to design and synthesize compound
libraries for biological screenings, i.e., diversity-ori-
ented synthesis (DOS) and biology-oriented synthesis
(BIOS).
Keywords. Chemical biology, biology-oriented synthesis (BIOS), diversity-oriented synthesis (DOS), com-
pound libraries.
Introduction
Since the isolation ofmorphine by Friedrich Sertrner
in 1805 and its subsequent validation as the active
principle of opium, the synthesis of small molecules
with biological activity has been one of the prime aims
of chemistry. Although Paul Ehrlich already at the
beginning of the 20th century noticed that the action
of drugs is explicable in terms of conventional
chemical interactions, drug discovery in its early
times was mainly based on trial and error, as the
molecular principles of drug action were not then
understood. With the advances in biological sciences
and especially the rise of structural biology allowing a
study of drug-protein interactions at an atomic level
during the second half of the 20th century, our
molecular understanding of the underlying principles
of drug action has increased dramatically. It is now
clear that small molecules exert their biological
activity by specific binding to defined regions on
their molecular targets, thereby modulating their
biological function.
This small molecule-induced modulation of protein
function represents the basis for medicinal chemistry
and chemical biology. However, while in medicinal
chemistry small molecules are sought to chemically
modify diseased states, e.g., by small molecule inhib-
ition of pathologically overexpressed enzymes, they
are used in chemical biology as chemical probes for
introducing an artificial and directed perturbation in a
biological system. A comparison of the perturbed and
non-perturbed state of the biological system then
allows an analysis of the functioning of the biological
system. This approach is complementary to existing
biological methods.
Importantly, although the specifications of small
compounds for medicinal chemistry or chemical
biology applications differ in detail, both approaches
rely on the availability of suitable small molecules.
These small molecules are usually identified by a
screening process in which a collection of compounds,
also referred to as “compound libraries”, are system-
atically surveyed for a proper small molecule probe.* Corresponding author.
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Consequently, the quality of the compound library is a
major determinant for successful screening.
Concepts for small molecule synthesis
The need for suitable chemical probes has led to
several concepts that try to give an answer to one of
the fundamental questions of chemical biology, i.e.,
which type of compounds should be synthesized and
employed in biochemical or biological screenings.
Unfortunately, this question cannot be answered
generally taking into account the various applications
for which small molecules can be used. The selection
for a certain type of compound is especially compli-
cated if the subsequent screening, e.g., in a phenotypic
screen, should be performed unbiased.
As a consequence, chemical biologists and medicinal
chemists have resorted to the synthesis of compound
collections or libraries to provide a defined set of
compounds for initial screening of various targets.
However, this approach is hampered by the enormous
range of chemical substances that in principle can be
synthesized, also referred to as “chemical space”.
Calculations have led to the proposition that 1063
different compounds with drug-like properties exist
in chemical space [1, 2]. Surely, such a gigantic number
of compounds is no longer comprehensively or
systematically amenable to synthesis. This dilemma
has spurred several different approaches to cover
extended regions of chemical structure space or to
identify regions of chemical space for which the
likelihood of obtaining biologically active compounds
is given or at least enhanced.
In this review, we want to present the underlying
concepts of two approaches for compound collection
development, i.e., diversity-oriented synthesis (DOS)
and biology-oriented synthesis (BIOS). While DOS
focuses on the generation of structurally diverse and
complex compound libraries, BIOS centers on the
generation of small compound libraries based on
scaffolds of proven biological relevance. Although
both concepts therefore rely on different design
concepts, they are not mutually exclusive, as either
DOS libraries of scaffolds of proven biological
relevance or BIOS libraries of a scaffold derived
fromDOS screening can be generated. Consequently,
compound libraries made under these guiding princi-
ples have been extensively studied in various screen-
ing campaigns and their potential has been well
proven as a source for biologically active small
molecules. Other well-validated approaches such as
fragment-based design or computational methods are
not covered by this review. The reader is referred to
other authoritative reviews [3–6].
Diversity-oriented synthesis
DOS as a principle for library synthesis
DOS has been introduced by Schreiber et al. [7] as a
new concept for compound library generation. The
term DOS has been coined to distinguish this ap-
proach from “traditional” synthesis that aims at the
synthesis of one defined compound also referred to as
the “target”. Such a target is often a natural product of
complex structure and the aim of the synthesis is to
obtain this compound in high efficiency and yield.
Consequently, this “classical” textbook synthesis
approach has been described as target-oriented syn-
thesis (TOS). Contrary to TOS, DOS targets the facile
preparation of collections of structurally complex and
also diverse compounds from simple starting materi-
als.
Towards this end, a new synthetic planning strategy is
required. In TOS a “retrosynthetic analysis” of the
desired target structure is employed (which means a
step-wise analysis of chemical transformations, start-
ing from the complex target structure towards more
simple starting materials). DOS requires a forward
“synthetic analysis” of the different reaction steps,
initiating from simple and similar starting materials
towards complex and diverse products (Fig. 1) [8, 9].
In this context, the two terms “structural complexity”
and “diversity” should be closer examined. Structur-
ally complex molecules exert a highly folded, pref-
erably rigid three-dimensional structure. As a rule of
thumb, structurally complex molecules often consist
of annulated ring systems, while linearmolecules show
significantly lower complexity. Diversity on the other
hand is a measure for the structural difference of the
compounds in a given library. However, for library
assessment it is usually difficult to exactly quantify
these two terms. Instead, they are normally used in a
more intuitive manner.
The importance of these two characteristics of com-
pound libraries started to become clear in the 1990s as
combinatorial chemistry for the first time allowed the
synthesis of large compound collections. The parallel
establishment of high-throughput screening (HTS)
made a rapid and reliable screening of these huge
libraries amenable. Although expectations in this
approach were high in the beginning, the results of
the screening campaigns were usually not very sat-
isfactory. However, a thorough statistical analysis of
the hit rates of different libraries revealed that
compound collections which contained more structur-
ally complex and diverse compounds usually yielded
much higher hit rates than libraries consisting of
“simple” compounds, highlighting their importance
for biological activity. In fact, the two quality factors,
library complexity and diversity, have to be regarded
Cell.Mol. Life Sci. Vol. 65, 2008 Review Article 1187
as even more important if compound collections are
used for phenotypic screens as the phenotypic readout
can be caused by a multitude of proteins derived from
different protein classes within a cell [10].
Therefore, the aim of the synthetic planning of a DOS
library as performed during the forward synthetic
analysis is to incorporate reaction pathways that lead
to an optimization of these two important factors
(Fig. 2).
Structural complexity for example has been intro-
duced in DOS libraries through the use of tandem- or
domino reactions. In these reactions, two or more
transformations are intimately coupled with each
other so that the product of the first reaction is used
as a substrate for the subsequent reaction (Fig. 3) [11].
Additionally, conformational analysis of macrocyclic
ring structures can be used to suggest suitable
scaffolds with high structural complexity. Using this
method, some medium-ring sized systems have been
the focus of DOS [12].
Structural diversity on the other hand can be imple-
mented by (a) generating different scaffolds or
skeletons by specialized reactions – a concept which
leads to “skeletal diversity”; (b) introducing “func-
tional group diversity”, i.e., changing the functional
groups at a given scaffold structure, or (c) synthesizing
different stereoisomers to access different binding
patterns with the binding partners – an approach
leading to “stereochemical diversity”. In general,
skeletal diversity can be achieved in several ways,
e.g., by building block diversity or by allowing one
intermediate to react according to different protocols
addressing distinct functional groups, which gives
access to structurally diverse products. Also substitu-
ent diversity can be used, i.e., the generation of
functional groups at different positions, which are
then further converted in the same way. One example
for such a reaction cascade is the introduction of
terminal olefins with different chain lengths and
subsequent ring closing metathesis. Other reactions
used include for instance ring expansion and aldol
reactions [13, 14]. Another synthetic approach to-
wards skeletal diversity as an example for implement-
ing structural diversity in compound libraries is
illustrated in Figure 4 [15].
The impact of structural complexity and diversity on
exploratory biological screening was probed and
demonstrated by Schreiber et al. [16] in another
study. In an extensive biological screening campaign
using 40 different cell-based assays, the influence of
stereochemical and skeletal diversity on biological
activity was tested. For this purpose, a library consist-
ing of 122 macrolides (Fig. 5A, structurally more
complex) and their 122 linear precursors (Fig. 5B,
structurally less complex) was employed. In addition,
the stereochemistry (markedwith an asterisk in Fig. 5)
of the compounds was systematically permuted to
examine the influence of stereochemical diversity.
Statistical analysis of the screening results revealed
that structurally more complex macrocycles were
significantly more active than linear derivatives. In




Figure 2. Forward synthetic analysis incorporates analysis of
reaction pathways that lead to structural complexity and diversity.
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addition, the macrocyclic compounds were also more
likely to exhibit activity in only one assay, indicating
that structural complexity also results in higher target
selectivity. The linear analogues (if active at all)
exerted activity in several assays, pinpointing towards
a connection between structural complexity and bio-
logical specificity. In addition, a hierarchical clustering
of the data also identified stereochemistry (i.e.,
stereochemical diversity) as a second dominant factor
in global activity patterns.
To achieve maximum efficiency in the library gener-
ation, the synthesis pathways in DOS should be
limited to three to five reaction steps. Thus, the
challenge in devising DOS libraries by forward
synthetic analysis lies in counterbalancing the conflict
between aiming at structurally complex and diverse
compounds on the one hand and synthesizing them in
as few steps as possible with high yields and efficiency
on the other hand. To achieve this difficult task,
special type of chemical reactions, so-called “com-
plexity-generating reactions”, have to be identified,
optimized and implemented into the synthetic path-
way.
Biological applications of DOS libraries
DOS libraries have been employed in manifold
different screens, ranging from cell-free protein bind-
ing, enzyme-linked immunosorbent assays (ELISA)
and fluorescence resonance energy transfer (FRET)
assays to cell-based reporter-gene, cytoblot and phe-
notype assays [17, 18]. In these screens, libraries
generated under the DOS principle proved to yield
Figure 3. An example of a synthetic strategy to obtain a compound library with high structural complexity. To achieve this, a tandemUgi
four component condensation-Diels-Alder reactionwas used. Further complexitywas then introduced through a subsequent ring-opening/
ring-closing metathesis reaction to provide structurally complex products containing two five-membered and two seven-membered rings.
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versatile small molecule probes for studying biology
with chemical genomics applications.
For example, a small molecule namedUretupamine B
(Fig. 6A) was found as a function-selective suppressor
of the yeast glucose signaling protein Ure2p from a
DOS library [19]. Ure2p regulates cellular responses
to different carbon and nitrogen nutrients by repres-
sing two transcription factors Nil1p and Gln3p. In
response to the nutrient-type, differential signaling
pathways are initiated. Consequently, a Ure2p knock-
out (ure2D) could not be used to study the Ure2p-
mediated regulation of the signaling pathways; how-
ever, a function-selective small molecule inhibitor
such as Uretupamine B was able to assist in this task.
In another study, a cell permeable small molecule
inhibitor HR22C16 (Fig. 6B) of the molecular motor
protein Eg5 was discovered from a DOS library [20].
A DOS library of medium ring-sized biaryls was used
in a plant phenotype screen. One compound, (P)-4k
(Fig. 6C) was found to severely affect plant develop-
ment, causing rigorous pigment loss and eventually
death to plants. In another screen with the same
library, which also contained linear compounds, a
derivative named (S)-13ab (Fig. 6D) was identified as
a small molecule probe for Danio rero (zebra fish)
development. This compound induced a strongly
retarded development even at a concentration of
100 nM, leading to lower than normal pigmentation,
weak hearts, abnormal brains and misshapen jaws by
day 2 after fertilization [21].
DOS approaches can also be used to generate analogs
of natural products, an approach which combines the
strengths of DOS and BIOS [22]. For example, a
10,000-member library of carpanone (Fig. 6E) was
synthesized. Screening of this library revealed various
vesicular traffic inhibitors by preventing exocytosis
from the Golgi apparatus, of which CLL-19 (Fig. 6F)
was the most potent one. Interestingly, the starting
structure carpanone did not exhibit any vesicular
traffic inhibition [23].
Clearly, these examples demonstrate the potential of
DOS libraries as a source for interesting biologically
active small molecule probes. In view of the ongoing
further developments and increasing availability of
DOS based libraries, a new toolbox for the “small
molecule biologist” is now available andwill influence
future research directions.
Figure 4. An example of a DOS approach towards skeletal diversity. Four different skeletons in a one-step synthesis were generated from
only one starting structure.
Figure 5. General chemical structures of compounds employed in
the screen (permuted chiral centers have been marked with an
asterisk). (A) Structures of macrocyclic library members (structur-
ally more complex). (B) Structures of linear library members
(structurally less complex).
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Biology-oriented synthesis
BIOS as a principle for library synthesis
While DOS seeks to limit chemical space by focusing
on structurally complex and diverse small molecules,
BIOS builds on the inspiration given by nature
through natural products. Natural products are de-
fined chemical entities that often display biological
activity. However, on its venture for low molecular
weight natural products with such biological activity,
nature itself explored only a tiny fraction of the
available chemical space during evolution. Interest-
ingly, the same holds true for the targets of those
natural products, which are mainly proteins. During
their evolution also only a tiny fraction of all possible
amino acid combinations could have been probed by
biosynthesis [24].
In addition, the three-dimensional folds of proteins
have been shown to be even more conserved during
evolution than their underlying sequence since similar
three-dimensional structures can be formed by differ-
ent sequences. This leads to the conclusion that the
natural product space as well as the protein structure
space explored by nature during evolution are strong-
ly limited in size and highly conserved [25, 26].
As a structural matching between the protein binding
site and its ligand is strictly required for a high-affinity
interaction, both the structure space of the proteins
and of their ligands have to be highly complementary.
The chemical space explored by natural products is
certainly not the only region compatible with protein
structure space but number and size of such regions in
chemical space can be expected to be limited. The
natural product space therefore is enriched with
bioactive structures and thus contains promising
starting points for the search of new bioactive
molecules.
Consequently, Waldmann and coworkers [27] forged
these complementary properties of bioactive small
molecules (either natural products or known drugs)
and their protein targets (receptors, proteins, trans-
porters, etc.) into a new concept for library synthesis,
termed BIOS. In this approach, library generation is
focused on compound classes from “biologically
relevant space”, e.g., the natural product or drug
space, and only scaffolds from this area of proven
relevance are selected as starting points for the design
and synthesis of small focused libraries with limited
diversity. BIOS, therefore, represents a conceptually
alternative approach and is complementary to other
library design concepts such as DOS. Moreover, with
BIOS, previously unrecognized relations between the
natural product and the protein world can be eluci-
dated, such as predicting target proteins of a natural
product-based library by bio- and cheminformatic
methods (Fig. 7).
Figure 6. Structures of small molecule probes derived from DOS libraries. (A) Uretupamine B; (B) HR22C16 analogue; (C) (P)-4k;
(D) (S)-13ab, (E) carpanone (no probe); (F) CLL-19.
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BIOS bases on and extends two concepts developed
earlier by Waldmann and colleagues [28]. In the first
concept, a “scaffold tree” that maps and correlates the
scaffolds of natural products in a hierarchical manner
was created. The resulting diagram results in a
“structural classification of natural products”
(SCONP) and allows charting of and navigation in
chemical space. In the second concept, “protein
structure similarity clustering” (PSSC), the biological
targets of small molecules, i.e., the proteins, are
classified into clusters employing structural similarity
around the ligand binding sites [29]. Both approaches
and the application of BIOS to design small molecules
are explained in more detail in the next sections.
SCONP in a scaffold tree
Natural products have a long history as starting points
for drug design, as evidenced by almost half of the
marketed drugs over the last 30 years having been
derived from natural products [30]. However, a
detailed analysis of the mode of action of natural
products revealed that their overall biological activity
is often a consequence of targeting multiple proteins.
Natural products usually interact with multiple pro-
teins during their biosynthesis as well as when they
exert their mode of action, which indicates that
structural information for protein recognition has
been encoded into their molecular structure during
evolution.
Consequently, the underlying scaffolds of natural
products have been recognized as privileged struc-
tures for library design for several years and explored
in library design [31]. To chart and visualize the
chemical space populated by natural products, Wald-
mann and coworkers [28] introduced a hierarchical
classification of their underlying scaffolds that is based
on their cyclic frameworks and linkers. The focus on
molecules containing ring structures is justified as
most small molecule inhibitors and drugs are based on
cyclic systems, which leads to a stiffening of the
molecule, resulting in enhanced target affinity due to
less entropy loss upon binding. Starting from complex
natural products, the scaffold was isolated based on
rings, linker chains and ring-based double bonds. A set
of defined rules derived from organic and medicinal
chemistry was subsequently used to step-wise decon-
struct the derived natural product scaffolds into
smaller parent structures. This reductionist approach
led to a unique scaffold tree, in which each scaffold in
the hierarchy represents a well defined chemical
entity and substructure of the original natural product.
Moreover, the scaffold tree puts more complex
scaffolds into relation with simpler framework, thus
representing an efficient procedure to reduce molec-
Figure 7. BIOS builds on biolog-
ically prevalidated structures, ei-
ther natural products or drugs,
and uses them as scaffolds for
library generation. In addition, it
allows an educated guess of pro-
tein targets of natural products
using protein similarity analysis
(see below).
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ular complexity from multiple annulated rings at the
outer rims of the scaffold tree tomonocyclic systems at
the most inner circle of the scaffold and allowing a
categorization of structural diversity in an intuitive
and chemically meaningful way (Fig. 8).
Within the scaffold tree, three scaffold classes can be
distinguished: nitrogen heterocycles, carbocycles and
oxygen heterocycles of which two to four ring systems
are most common. The significance of the natural
product tree lies in its descriptive representation of
biologically relevant scaffolds for the design and
synthesis of focused compound collections.Moreover,
it allows a correlation of different scaffold classes as
performed during BIOS (see the BIOS section for
more details). Based on this tree, Waldmann and
coworkers synthesized libraries featuring spiroketal
[32–34], a,b-unsaturated lactone [35–40], tetrahy-
dropyrane [41, 42], indolactam [43, 44], decaline [45–
48], indole scaffolds [49, 50] and indoloquinolizidine
[27, 51], and proved their biological activity in various
screening campaigns, thereby validating the scaffold
tree approach as a powerful method for generating
libraries with high contents of biologically active
molecules. For example, two cell-based screens of a
library consisting of only 50 a,b-unsaturated d-lac-
tones yielded small molecule modulators of cell cycle
progression (Fig. 9A) and of viral entry via the
secretory pathway (Fig. 9B) [40]. Using a library
based on [5.5]spiroketals a modulator of the tubulin
cytoskeleton in breast cancer cells was identified
(Fig. 9C) [33]. In addition, several libraries based on
natural product scaffolds have been screened for
enzyme inhibition. Figure 9D shows a representative
example that was derived from an indoloquinolizidine
compound library and exerts potent inhibition of the
phosphatase MptpB of Mycobacterium tuberculosis
[27].
Figure 8. Ascaffold tree generated in the structural classification of natural products (SCONP). For clarity, only scaffolds that represent at
least 0.2% of the natural products described in the Dictionary of Natural Products (DNP) database have been sketched.
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PSSC for identifying conserved protein-binding
sites
Proteins are built from one or several domains that
can be classified by their fold types. These folds
describe the spatial arrangement of secondary struc-
ture elements such as a-helices and b-sheets into
defined motifs that have been found as conserved in
nature and during evolution [52–55]. Consequently,
different fold types were summarized in a structural
classification of proteins (SCOP) database in which
about 1000 distinct folds have been described up to
now [56, 57]. Although computational genome anal-
ysis predicts that between 1000 and 10,000 different
folds should exist in nature, the vast majority of
proteins are expected to be built up from roughly 1000
of the most abundant folds [58–60]. The fold defines
the three-dimensional structure of the protein back-
bone, aswell as the shape and size of the active site and
the spatial arrangement of the catalytic residues, while
the different amino acid sequence of the proteins fine-
tunes the exact shape of the binding pockets within the
active site. As a consequence, only the combination of
fold and sequence determines the binding properties
of a protein and thus enables the enormous number of
different functions to be carried out by a limited
number of folds [25, 61–63].
As revealed by SCONP, the number of scaffolds
explored by natural products is also limited and
conserved (see previous section) [64]. However, the
implementation of different substitution patterns of
the scaffold leads in the end to a vast number of
possible compounds. This analogy between the pro-
tein and natural product world has been diagnosed by
Waldmann and colleagues and has led to the hypoth-
esis of a complementary relation between different
protein folds and the scaffolds of natural products,
similar to the existing complementarity of small
molecules and their binding sites (Fig. 10) [29, 65–70].
If this proposition holds true, it would allow a
prediction of suitable small molecule scaffolds for
targeting a whole group of structurally similar pro-
teins. Importantly, this prediction would be exclusive-
ly based on structure and natures conservatismduring
evolution.
However, as described earlier, the binding pocket is
shaped by the individual side chains of the amino acids
constituting the fold. Consequently, library synthesis
of an identified scaffold is necessary to optimize its
Figure 9. Structures of biologi-
cally active small molecules de-
rived from SCONP-based com-
pound libraries.
Figure 10. A complementary in-
teraction between proteins and
small molecules is the basis for
binding. A similar complementa-
ry interaction might exist on the
level of protein folds and natural
product scaffolds.
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substitution pattern for the distinct binding site. To
illustrate this in a more comprehensive example, one
could imagine two nearly identical binding sites as
generated by a similar fold. However, in the first case,
a negative charge resides in a binding pocket of a
protein while in the second case a positive charge is
located there. Consequently, as the small molecules
have to be complementary to the binding site, the
scaffold structure has to be decoratedwith a positively
charged side chain to target the proteinwith a negative
charged pocket. However, the same compound would
not bind to the second protein, as the two positive
charges would induce repelling. This example clearly
demonstrates that, while similar folds bind similar
scaffolds, it is also necessary to generate sufficient
chemical diversity to match biological diversity in the
quest for biologically active molecules/ligands for
proteins.
PSSC relies on bio- and cheminformatic algorithms
and analysis of existing data, e.g., from the Protein
Data Bank (PDB) to identify proteins in which the
subfold around the ligand-binding site, the so-called
“ligand-sensing core”, is similar. Structures that show
structural similarity of the ligand-sensing cores are
assigned to one protein structure similarity cluster. If a
ligand for one member of the cluster is known, the
scaffold of this ligand can then be expected to be a
prevalidated starting point for the synthesis of ligands
for the other members of the protein cluster. Con-
sequently, members of a library of synthesized deriv-
atives based on the scaffold should target several
members of the protein cluster.
This concept was proven by a recent study with the
natural product dysidiolide. Dysidiolide [71] targets
the Cdc25A phosphatase that is involved in cell cycle
regulation and represents a promising target for the
development of novel anti-cancer agents [72–74]. A
protein structure similarity analysis revealed that
similar ligand binding sites are found in acetylcholine
esterase (AChE) with a root mean square deviation
(RMSD) of the aligned Ca traces of 2.74  over 49
residues and a sequence identity of 8.2% [75].
Another member of the protein similarity cluster is
11b-hydroxysteroid dehydrogenase with an RMSD of
4.13  to Cdc25A over 80 aligned residues and a
sequence identity of 5.0% [76–79].
Waldmann and coworkers therefore assumed that
dysidiolide might represent a starting point for the
development of inhibitors of the other two members
of the protein cluster. Consequently, the hydroxybu-
tenolide part of the natural product was used as a
scaffold for library development as it was assumed to
be the active motif for phosphatase inhibition. A
library of 150 compounds built around this scaffold
was screened and revealed three hits for AChE in the
low micromolar range (IC50 values of 1.7–6.9 mM).
For 11b-hydroxysteroid dehydrogenase, seven hits
with IC50 values from 2.4 to 10 mM were found.
Moreover, for one compound a pronounced selectiv-
ity between the two isoforms of 11b-hydroxysteroid
dehydrogenase was determined (Fig. 11). These re-
sults demonstrated unequivocally the potential of the
PSSC approach as a guiding principle for compound
development [29].
Another demonstration of the impact of PSSC can be
made from a survey of literature data. The farnesoid
X receptor (FXR) is a nuclear hormone receptor
involved in development and homeostasis and plays
key roles in diseases such as obesity, diabetes and
cancer [80, 81] . A PSSC analysis of FXR disclosed a
structural similarity to estrogen receptor b (ERb)
[82] and the peroxisome proliferation-activated re-
ceptor g (PPARg) [83] . Although exhibiting a similar
fold pattern, their sequence similarities are below
20% (Fig. 12). However, as all three proteins were
located in the same PSSC cluster, it should be
possible to find a common scaffold class acting as
general modulators of FXR, ERb and PPARg. A
literature search revealed that the natural product
genistein, which is based on a benzopyran scaffold, is
a known inhibitor of ERb and PPARg [84] . The drug
troglitazone also based on a benzopyran scaffold is a
known PPARgmodulator [85] . Interestingly, a high-
throughput screening for FXR inhibitors with a
10,000-member benzopyran library resulted in sev-
eral hits, as would have been predicted by PSSC [86,
87]. In addition, the benzopyran library also yielded
ligands for other members of the PSSC cluster,
thereby further supporting the application of PSSC
in library design.
Besides using X-ray or NMR protein structures, high-
quality homology models can also be employed for
PSSC, further extending its use. In a recent study, an
additional method that also considers protein flexi-
bility was introduced to the PSSC procedure. Molec-
ular dynamics calculations generated different protein
conformations, which are then tested for possible
binding sites; using this modified procedure the ligand
binding sites previously undetected by “static” PSSC
were identified [88].
Moreover, the scope of PSSC can be extended by
moving beyond structural similarity between targets,
e.g., by including similarities between biosynthetic
enzymes and other proteins. Quinn et al. [89, 90]
proposed that the structural similarity between bio-
synthetic enzymes and other proteins could provide a
link to identify new inhibitors. In their approach,
proteins were grouped according to known inhibition
data and subsequently searched for common struc-
tural motifs that may encode for the binding proper-
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ties. Although this procedure is quite different from
PSSC, which starts from structural comparisons, the
underlying logic should also be applicable in the PSSC
approach, which could then be used to cluster
biosynthetic enzymes and potential targets based on
a structural similarity.
In summary, PSSC represents an alternative approach
for compound library development. The grouping of
Figure 11. Protein structure sim-
ilarity clustering (PSSC) of
Cdc25A phosphatase (red in left
PSSC and green in right PSSC,
respectively) and acetylcholine
esterase (blue, right PSSC) and
11b-hydroxysteroid dehydrogen-
ase (red, left PSSC). Synthesis of
a library of analogues yielded
several hits for these two proteins
with a similar fold in the binding
pocket.
Figure 12. (A) Structures of ben-
zopyran-based ligands for ERb,
PPARg and FXR. (B) Superim-
position of the X-ray structures
of ERb complexedwith genistein
(III), PPARg with rosiglitazone
and FXR
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proteins opens new routes to small molecule inhibitor
design as it allows the transfer of knowledge about the
interaction of a small molecule with its protein target
to awhole cluster of proteins.Moreover, it can be used
to predict possible target proteins of small molecules.
Besides its use for screening applications during drug
discovery, it might also find application for identifying
cross-inhibitions of proteins to foresee unwanted drug
side effects during drug development.
Merging SCONP and PSSC leads to BIOS
SCONP and PSSC are novel principles for the design
of biologically prevalidated compound collections. A
merging of these two approaches into one concept,
i.e., BIOS, leads to synergistic effects, providing, for
example, an approach to simplify structures of known
inhibitorswhile retaining their basic biological activity
[27, 37, 40, 51].
The scaffold tree approach arranges scaffolds of
natural products in a tree-like structure with the
inner segments of the tree representing less complex
scaffolds. Consequently, moving inward along the
branches (brachiation) of the tree to reach regions
populated by less complex scaffolds leads to a
structural simplification of the scaffolds. While struc-
tural simplifications of scaffold structures have been
tried many times before with varying success, the
scaffold tree offers a reduced set of simplifications
pre-selected on the basis of organic and medicinal
chemistry knowledge. This may lead to situations in
which it may not be possible to choose the obvious
retrosynthetic disconnection but rather the solution
suggested by the scaffold tree.
This novel concept was first applied in a study
involving the Cdc25A phosphatase protein cluster
derived from PSSC, consisting of Cdc25A phospha-
tase, AChE and 11b-hydroxysteroid dehydrogenase
(11bHSD) and the scaffold tree of the complex natural
product glycyrrhetinic acid, a known ligand of
11bHSD (Fig. 13).
SCONP analysis of glycyrrhetinic acid enabled a
stepwise reduction of complexity from its pentacyclic
Figure 13. BIOS is based on the merging of PSSC and SCONP. The scaffold tree of glycyrrhetinic acid was analyzed by SCONP rules,
leading to an octahydronaphtalene scaffold that represents a substructure of dysidiolide, a known Cdc25A inhibitor.
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scaffold to monocyclic systems, suggesting several
possible scaffolds for library synthesis. Therefore, the
final decision about which ring scaffold should be
explored in library synthesis was based by a second
criteria, which was derived from PSSC. Glycrrhetinic
acid is a known 11bHSD modulator and is part of a
PSSC cluster with Cdc25A and AChE. Dysidiolide
contains a particular dehydrodecaline system and
Cdc25A, its natural receptor, is also part of the cluster,
which renders the dysidiolide dehydrodecaline core
scaffold a viable starting point for the design of a
library of molecules targeting 11bHSD [72, 76]. Using
this concept, a library of ca. 500 dehydrodecaline
compounds was synthesized, of which 162 compounds
were tested in a biochemical 11bHSD inhibition assay.
Remarkably, among these, 30 inhibitors with IC50
values below 10 mM were found, of which four of
them even displayed inhibitory activities between 310
and 740 nM. Moreover, the most potent inhibitors
also proved bioactivity in cellular assays (Fig. 14) [28].
In a second example, structurally complex alkaloids,
namely yohimibine and ajmalicine, were identified as
moderate Cdc25A phosphatase inhibitors. The
SCONP analysis of these natural products led to a
scaffold tree, ranging from the parent pentacyclic over
tricyclic indole-based scaffolds to monocyclic rings.
Library synthesis of indoloquinolizidines (tetracyclic
systems) revealed two compounds with IC50 values
comparable to the natural products. Moreover, ex-
tending the screen to other phosphatases allowed the
elucidation of structurally new inhibitors of the M.
tuberculosisprotein tyrosine phosphataseB (MPTPB)
from the same library. Structurally simpler com-
pounds with three- and two-membered rings also
yielded another inhibitor of Cdc25A with a similar
IC50 value as the natural products and also contained
an inhibitor of the protein tyrosine phosphatase 1B
(PTP1B) and eight inhibitors of MPTPB in the
submicromolar range [27, 51].
A more elaborate set of rules was developed by
Schuffenhauer et al. [91], which consists of 13 rules
and was designed to reflect more the thinking of a
medicinal chemist. Moreover, this rule set produces
more transparent parent-child assignments, i.e., a
given parent scaffold will always be deconstructed to
the same child scaffold independent of the underlying
dataset. This characteristic allows easy extension of
scaffold tree to new molecules and integration of
virtually any complex molecule at the outer fringes of
the scaffold tree. Schuffenhauer et al. [91] also showed
a correlation of the scaffold hierarchy with bioactivity
indicating that brachiation may indeed yield simpler
molecules with comparable bioactivity.
The separation of scaffolds and side chains is a
common paradigm in medicinal chemistry processes,
e.g., in hit-to-lead optimization. BIOS, however,
facilitates hit generation, and it does so in two ways.
It provides scaffolds prone to bind the target protein
Figure 14. Merging PSSC and
SCONP to BIOS for the devel-
opment of 11bHSD inhibitors.
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and structurally simpler relatives as a starting point for
library design. In design of the compound collection,
side chain diversity is the key to increasing the
probability of finding good hits by matching the
distinct interaction pattern of the target selectively.
BIOS also generates a target cluster that can be used
to identify cross-inhibition and selectivity profiles
very early on. In general, BIOS is well suited to
provide starting points in the design of small com-
pound collections for the discovery of initial hits.
In summary, these examples demonstrated that a
combined use of SCONP and PSSC as proposed in
BIOS represents an intriguing approach for the
structural simplification of natural products, re-
quired for focused library synthesis. Although gen-
erality of the concept cannot yet be claimed by only
two examples, and the brachiation approach cannot
be expected to work for all scaffolds and proteins, it
has been shown in principle that a combined use of
SCONP and PSSC provides an advantageous oppor-
tunity for the design of structurally simplified protein
ligands based on complex natural product structures.
Therefore, BIOS represents a versatile approach for
library synthesis as it significantly enhances the
chance of devising and finding modulators of pro-
teins, a challenge which lies at the heart of chemical
biology.
Conclusions and future prospects
The need for suitable small molecules for the future
advancement of chemical biology has spurred the
development of novel approaches for small molecule
library design. From these, the two concepts of DOS
and BIOS are discussed in this review. While DOS
builds on general considerations of small molecule
properties and tries to forge them into the target
molecules, BIOS relies on biological prevalidation
and conservatism during evolution in protein and
natural product structures to identify biologically
relevant substructures of vast chemical space. As a
consequence, DOS usually leads to the generation of
large libraries for exploring larger areas of chemical
space. BIOS, however, prefers small focused libraries
exploring a well-defined part of chemical space
previously identified as of relevance to the particular
problem. Key to this concept is the postulate of
structural complementarity between similar proteins
and their ligands.
Both approaches have the potential to deliver high-
quality small molecule libraries, thereby laying the
foundation for future advances in the field of chemical
biology research and drug discovery. Libraries gen-
erated under one of these two principles are becoming
increasingly available to the scientific community and
their contribution to the exploration of biology will
become measurable within the coming years.
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